| 1 Leaving the study early: 1. Any reason |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 1.1 short term |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
1.0 [0.06, 15.48] |
| 2 Global state: 1. Change over time ‐ no better or deterioration (ITT) |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 2.1 short term |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
1.30 [0.93, 1.83] |
| 3 Behaviour: 1. Behaviour subscale of the Psychiatric Rating Scale: no better or worse |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
1.18 [0.90, 1.55] |
| 4 Adverse events: Movement disorders |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 4.1 akathisia ‐ short term |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
0.58 [0.25, 1.34] |
| 4.2 ataxia ‐ short term |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
1.0 [0.21, 4.68] |
| 4.3 dyskinesia ‐ short term |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
1.5 [0.26, 8.53] |
| 4.4 parkinsonism ‐ short term |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
0.8 [0.48, 1.32] |
| 4.5 use of antiparkinsonian drugs ‐ short term |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
1.18 [0.81, 1.73] |
| 5 Other adverse events: 1. Anticholinergic |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 5.1 blurred vision ‐ short term |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
0.29 [0.06, 1.30] |
| 5.2 dry mouth ‐ short term |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
1.0 [0.38, 2.61] |
| 6 Other adverse events: 2. Arousal |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 6.1 insomnia ‐ short term |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
0.71 [0.39, 1.29] |
| 6.2 need of additional benzodiazepines ‐ short term |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
1.0 [0.21, 4.68] |
| 6.3 sleepiness/sedation ‐ short term |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
0.9 [0.41, 1.99] |
| 7 Other adverse events: 3. At least one |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 7.1 short term |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
0.90 [0.68, 1.20] |
| 8 Other adverse events: 4. Cardiovascular |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 8.1 faintness, dizziness, weakness ‐ short term |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
| 9 Other adverse events: 5. Central nervous system |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 9.1 disturbance of consciousness ‐ short term |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
| 9.2 headache ‐ short term |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
2.0 [0.19, 21.24] |
| 9.3 paraesthesia ‐ short term |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
5.0 [0.25, 101.18] |
| 10 Other adverse events: 6. Gastrointestinal |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 10.1 constipation ‐ short term |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
1.2 [0.40, 3.64] |
| 10.2 icterus ‐ short term |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
0.33 [0.01, 7.96] |
| 10.3 loss of appetite ‐ short term |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
0.88 [0.35, 2.20] |
| 10.4 nausea and vomiting ‐ short term |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
| 11 Other adverse events: 7. Skin |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 11.1 rash ‐ short term |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
3.0 [0.13, 71.65] |
| 12 Other adverse events: 8. Genitourinary |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 12.1 micturition disturbances ‐ short term |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
| 13 Other adverse events: 9. Others |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 13.1 cramps ‐ short term |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
0.33 [0.01, 7.96] |
| 13.2 sweating ‐ short term |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
1.0 [0.06, 15.48] |
